Figure 2
Figure 2. Generation of CD34+ cells from PDB4-treated hESCs after treatment with VEGF-A and bFGF. (A) and (B) Relative mRNA levels of CD34 between experimental groups. Error bars indicate the mean ± SD of 3 independent experiments. A P value < .05 was considered to be statistically significant (*P < .05; n = 3). (C) Proportion of CD34+ cells derived from CHA-hES4 and hiPSCs. PDB4-treated hESCs were cultured in VEGF-A and bFGF-containing medium for 6 and 9 days. The percentage of CD34+ cells (n = 3) is indicated as mean ± SD. (D) Coexpression of CD34 and CD31 in isolated CD34+ cells (n = 2). (E) Transcriptional expression of vascular-lineage genes (α-SMA, VE-CADHERIN, and CD31) and hematopoietic-lineage genes (β-GLOBIN, ϵ-GLOBIN, ζ-GLOBIN, RUNX1, and LMO2) in CD34+ cells. Abbreviations: Control, untreated hESCs; VE, VEGF-A; bFGF, bFGF; Vb, VEGF-A and bFGF; B4Vb, BMP4, VEGF-A and bFGF.

Generation of CD34+ cells from PDB4-treated hESCs after treatment with VEGF-A and bFGF. (A) and (B) Relative mRNA levels of CD34 between experimental groups. Error bars indicate the mean ± SD of 3 independent experiments. A P value < .05 was considered to be statistically significant (*P < .05; n = 3). (C) Proportion of CD34+ cells derived from CHA-hES4 and hiPSCs. PDB4-treated hESCs were cultured in VEGF-A and bFGF-containing medium for 6 and 9 days. The percentage of CD34+ cells (n = 3) is indicated as mean ± SD. (D) Coexpression of CD34 and CD31 in isolated CD34+ cells (n = 2). (E) Transcriptional expression of vascular-lineage genes (α-SMA, VE-CADHERIN, and CD31) and hematopoietic-lineage genes (β-GLOBIN, ϵ-GLOBIN, ζ-GLOBIN, RUNX1, and LMO2) in CD34+ cells. Abbreviations: Control, untreated hESCs; VE, VEGF-A; bFGF, bFGF; Vb, VEGF-A and bFGF; B4Vb, BMP4, VEGF-A and bFGF.

Close Modal

or Create an Account

Close Modal
Close Modal